Related Experiment Video
Updated: May 25, 2025
Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
Published on: March 15, 2024
LINC01088 prevents ferroptosis in glioblastoma by enhancing SLC7A11 via HLTF/USP7 axis
Yujie Zhou1, Zhen Zhao1, Cheng Jiang1
1Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Background:
Glioblastoma multiforme (GBM)is a highly aggressive malignancy of the central nervous system characterized by poor survival rates. Ferroptosis, an iron-dependent cell death pathway, is a promising therapeutic target for GBM. However, current treatments targeting cell death pathways have not yielded expected results. Long noncoding RNAs (lncRNAs) have been implicated in tumour proliferation, however, their role in ferroptosis in GBM remains underexplored. This study investigated the interplay between the lncRNA LINC01088 and ferroptosis in GBM to identify novel therapeutic strategies.
Methods:
We conducted gain- and loss-of-function studies to assess the impact of LINC01088 on GBM tumourigenesis and ferroptosis both in vitro and in vivo. Bioinformatics, dual-luciferase reporter assays, chromatin immunoprecipitation, RNA pulldown, mass spectrometry, RNA immunoprecipitation (RIP), and transcriptome sequencing were utilized to elucidate the mechanisms underlying LINC01088 expression and its downstream effects on ferroptosis.
Results:
The transcription factor specificity protein 1 (SP1) was identified as the promoter of LINC01088 transcription, which facilitated GBM progression. LINC01088 was found to inhibit ferroptosis and promote malignancy. Mechanistically, LINC01088 stabilized HLTF by enhancing its interaction with USP7 and preventing ubiquitin-mediated degradation. The stabilization of HLTF led to the upregulation of SLC7A11, which inhibits ferroptosis in GBM. Rescue experiments confirmed that altering HLTF levels reversed the ferroptotic phenotypes associated with LINC01088 modulation.
Conclusion:
This study revealed a novel SP1/LINC01088/HLTF/USP7/SLC7A11 axis that regulates ferroptosis in GBM, highlighting LINC01088 as a potential therapeutic target for ferroptosis-dependent GBM treatment.
Key Points:
LINC01088 is transcriptionally upregulated by SP1. LINC01088 acts as a scaffold platform to bind USP7 and HLTF. USP7, as a deubiquitinating enzyme of HLTF, participates in inhibiting the ubiquitin-proteasome degradation of HLTF. HLTF transcriptionally upregates the expression of downstream SLC7A11, and ferroptosis of GBM cells was inhibited.
Insights
This study reveals that the long noncoding RNA LINC01088 promotes glioblastoma multiforme (GBM) progression by inhibiting ferroptosis. Targeting the SP1/LINC01088/HLTF pathway offers a novel therapeutic strategy for GBM.
Area of Science:
- Neuro-oncology
- Molecular Biology
- Cancer Research
Background:
- Glioblastoma multiforme (GBM) is an aggressive brain cancer with poor outcomes.
- Ferroptosis, an iron-dependent cell death, is a potential therapeutic target for GBM.
- The role of long noncoding RNAs (lncRNAs) in GBM ferroptosis is largely unknown.
Purpose of the Study:
- Investigate the role of lncRNA LINC01088 in GBM.
- Elucidate the mechanism by which LINC01088 affects ferroptosis in GBM.
- Identify novel therapeutic targets for GBM treatment.
Main Methods:
- In vitro and in vivo gain- and loss-of-function studies.
- Bioinformatics, dual-luciferase reporter assays, ChIP, RNA pulldown, and RIP.
- Mass spectrometry and transcriptome sequencing to identify molecular mechanisms.
Main Results:
- Specificity protein 1 (SP1) upregulates LINC01088, promoting GBM.
- LINC01088 inhibits ferroptosis by stabilizing HLTF via USP7 interaction.
- HLTF upregulates SLC7A11, suppressing ferroptosis in GBM cells.
Conclusions:
- A novel SP1/LINC01088/HLTF/USP7/SLC7A11 signaling axis regulates ferroptosis in GBM.
- LINC01088 is a potential therapeutic target for GBM treatment.
- Targeting this axis may offer new strategies for ferroptosis-dependent GBM therapy.
